Remedy Robotics Partners with Mission Thrombectomy to Enhance Global Stroke Treatment Access
In a groundbreaking move that aims to enhance the accessibility of thrombectomy treatments for stroke patients, Remedy Robotics, Inc. has announced a strategic partnership with Mission Thrombectomy. This collaboration comes at a crucial time, as the need for timely and effective stroke intervention becomes more evident. Remedy Robotics specializes in developing cutting-edge medical technology, including the world's first remotely operated robot for endovascular interventions, known as the N1 System.
As part of this partnership, Remedy will serve as the exclusive robotics partner for Mission Thrombectomy, which is renowned for its global clinical network dedicated to advancing endovascular thrombectomy - a gold-standard treatment for acute ischemic stroke. This network spans over 100 countries, combining expertise from some of the world's leading specialists in the field.
Access to timely and effective stroke treatment is a significant challenge, especially in underserved areas. The recent MT-GLASS study showed alarming statistics: only about one-third of Americans can receive endovascular thrombectomy without delay. In contrast, low-income countries face even harsher realities, where less than 1% have access to such life-saving procedures. The data highlights not only the desperate need for improvement in access but also the critical role of innovation in addressing these gaps.
Dr. David Bell, CEO and Co-Founder of Remedy Robotics, expressed his enthusiasm about the partnership. He stated, “We are thrilled that Mission Thrombectomy has selected Remedy Robotics as its exclusive robotics partner to expand access to endovascular thrombectomy for stroke patients both in the U.S. and worldwide.
As part of this partnership, Remedy will serve as the exclusive robotics partner for Mission Thrombectomy, which is renowned for its global clinical network dedicated to advancing endovascular thrombectomy - a gold-standard treatment for acute ischemic stroke. This network spans over 100 countries, combining expertise from some of the world's leading specialists in the field.
Access to timely and effective stroke treatment is a significant challenge, especially in underserved areas. The recent MT-GLASS study showed alarming statistics: only about one-third of Americans can receive endovascular thrombectomy without delay. In contrast, low-income countries face even harsher realities, where less than 1% have access to such life-saving procedures. The data highlights not only the desperate need for improvement in access but also the critical role of innovation in addressing these gaps.
Dr. David Bell, CEO and Co-Founder of Remedy Robotics, expressed his enthusiasm about the partnership. He stated, “We are thrilled that Mission Thrombectomy has selected Remedy Robotics as its exclusive robotics partner to expand access to endovascular thrombectomy for stroke patients both in the U.S. and worldwide.
Topics Other）
【About Using Articles】
You can freely use the title and article content by linking to the page where the article is posted.
※ Images cannot be used.
【About Links】
Links are free to use.